Thesis

73 Grey zone amyloid burden REFERENCES 1. Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimer’s & Dementia. 2018;14(4):535-62. 2. Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO molecular medicine. 2016;8(6):595-608. 3. Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. The Lancet Neurology. 2013;12(4):357-67. 4. Jack CR, Jr., Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. The Lancet Neurology. 2013;12(2):207-16. 5. van Harten AC, Smits LL, Teunissen CE, Visser PJ, Koene T, Blankenstein MA, et al. Preclinical AD predicts decline in memory and executive functions in subjective complaints. Neurology. 2013;81(16):1409-16. 6. van Harten AC, Visser PJ, Pijnenburg YA, Teunissen CE, Blankenstein MA, Scheltens P, et al. Cerebrospinal fluid Abeta42 is the best predictor of clinical progression in patients with subjective complaints. Alzheimer’s & dementia : the journal of the Alzheimer’s Association. 2013;9(5):481-7. 7. Timmers T, Ossenkoppele R, Verfaillie SCJ, van der Weijden CWJ, Slot RER, Wesselman LMP, et al. Amyloid PET and cognitive decline in cognitively normal individuals: the SCIENCe project. Neurobiology of aging. 2019;79:50-8. 8. Vos SJB, Xiong C, Visser PJ, Jasielec MS, Hassenstab J, Grant EA, et al. Preclinical Alzheimer’s disease and its outcome: a longitudinal cohort study. The Lancet Neurology. 2013;12(10):957-65. 9. Mormino EC, Betensky RA, Hedden T, Schultz AP, Amariglio RE, Rentz DM, et al. Synergistic effect of beta-amyloid and neurodegeneration on cognitive decline in clinically normal individuals. JAMA neurology. 2014;71(11):1379-85. 10. Buckley RF, Sikkes S, Villemagne VL, Mormino EC, Rabin JS, Burnham S, et al. Using subjective cognitive decline to identify high global amyloid in community-based samples: A cross-cohort study. Alzheimer’s & dementia (Amsterdam, Netherlands). 2019;11:670-8. 11. Slot RER, Sikkes SAM, Berkhof J, Brodaty H, Buckley R, Cavedo E, et al. Subjective cognitive decline and rates of incident Alzheimer’s disease and non-Alzheimer’s disease dementia. Alzheimer’s & dementia : the journal of the Alzheimer’s Association. 2019;15(3):465-76. 12. Clark CM, Pontecorvo MJ, Beach TG, Bedell BJ, Coleman RE, Doraiswamy PM, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: a prospective cohort study. The Lancet Neurology. 2012;11(8):669-78. 3

RkJQdWJsaXNoZXIy MjY0ODMw